Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Riley who wrote (19045)	11/24/1998 10:21:00 AM
From: R Hamilton	Read Replies (1) \| Respond to of 120523

usai looks good....they have large stake in up coming tickmaster on-line ipo. rhonda

To: Riley who wrote (19045)	11/24/1998 12:21:00 PM
From: Jenna	Read Replies (3) \| Respond to of 120523

OXGN.. pretty similar to ENZN..both are small stocks with 'promising' drugs on their drawing board. I would not put my life savings into either one of them but they are both good for 'pops' when the word 'promising' is used related to their latest drug study. They retreat as quickly as they rise, but I would not be averse to holding 500-1,000 of each of these long term through their rollercoaster rides. If you are looking for a 'finish line' in this race. I think ENZN has the edge with its drug. Enzon Announces PEG-INTRON A Advances to Phase III for Chronic Myelogenous Leukemia PISCATAWAY, N.J.--(BUSINESS WIRE)--Nov. 20, 1998--Enzon, Inc. (NASDAQ:ENZN - news) announced today that Schering-Plough Corporation (NYSE:SGP - news) has advanced PEG-INTRON A®, a long-acting dose formulation of Schering-Plough's INTRON® A, into Phase III for chronic myelogenous leukemia. PEG-INTRON A is in Phase III for hepatitis C and malignant melanoma and is in early phase clinical trials for solid tumors, as well as in combination with REBETOL® for hepatitis C. ________________________________________ Shares of Oxigene, Inc. advanced 27 percent after the biopharmaceutical company reported promising results from its cancer therapy Combretastatin A-4 Prodrug. Oxigene (OXGN) said the study found that Combretastatin increased tumor cell death when used in combination with radiation, compared to radiation alone. Combretastatin, which is an anti-tumor vascular targeting agent, recently entered Phase I studies in the U.S. and U.K. in patients with cancer in advanced stages.